U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07359014) titled 'Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma' on Dec. 31, 2025.
Brief Summary: This study aims to investigate the efficacy and safety of CD19/BCMA CAR-T cells in treating relapsed/refractory multiple myeloma.
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Relapse Multiple Myeloma
Intervention:
OTHER: Dual CD19/BCMA CAR-T
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy
Recruitment Status: RECRUITING
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Published by HT Digital Content Services with permission from Hea...